Compare AbCellera Biologics Inc (ABCL) vs 8x8 Inc (EGHT) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

EGHT (8x8, Inc.) trades at $1.94, up 6.01% today, with a bullish technical signal despite bearish moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 EPS versus $0.07 expected. Recent news highlights AI product launches and industry recognition, including being named a 2026 MetriStar Top Provider for CPaaS. However, the company reported a net loss of $27.21 million for 2025, though projections show potential profitability improvement in 2026.

The outlook remains cautiously optimistic with analyst consensus showing 39% buy ratings but mixed technical indicators. Key opportunities include continued AI product adoption and revenue growth momentum, while risks center on profitability challenges, high debt levels, and competitive pressures in the communications platform market.